Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

Question 2

How does HMBD-001 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers clinical trial (NCT05910827). Contact the study team or your healthcare provider for specific answers.

What this study is about